Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 7/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 0.46 |
| ▸ | AGL | P35573 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.45 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radicamine B SCHEMBL8118948 | 1.00 | MGAM (1.00) | MGAMGLAAGLGAAGBA2 | |
| Radicamine B SCHEMBL13848027 | 1.00 | MGAM (1.00) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL19258270 | 0.85 | MGAM (0.73) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL13538449 | 0.85 | MGAM (0.73) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL17622803 | 0.85 | MGAM (0.73) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL8124475 | 0.84 | MGAM (0.72) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL8124155 | 0.84 | MGAM (0.72) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL9789772 | 0.83 | MGAM (0.71) | MGAMGLAAGLGAAGBA2 | |
| Ammonia Solution, Strong SCHEMBL8108711 | 0.78 | MGAM (0.64) | MGAMGLAAGLGAAGBA2 | |
| SCHEMBL8119254 | 0.77 | MGAM (0.62) | MGAMGLAAGLGAAGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | MGAM 36/4885GLA 13/4885AGL 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.